{"title":"家族性高胆固醇血症分子遗传学诊断的过去、现在和未来","authors":"E. Thomas","doi":"10.2217/clp.15.29","DOIUrl":null,"url":null,"abstract":"Abstract Familial hypercholesterolemia (FH) is the most common single gene disorder of lipid metabolism. Identifying the genetic cause of FH affects the management of the patient and their family members. Traditional genetic testing methods have been limited by throughput and cost, and therefore the majority of patients have not received a molecular diagnosis. Genetic testing technology has made huge advances in recent years, and these advances are now being translated to improve clinical diagnostic testing for many genetic disorders including FH. This review describes these advances in genetic testing, and considers their implications for the diagnosis and treatment of FH.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"13 1","pages":"379 - 385"},"PeriodicalIF":0.0000,"publicationDate":"2015-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The past, present and future of molecular genetic diagnosis in familial hypercholesterolemia\",\"authors\":\"E. Thomas\",\"doi\":\"10.2217/clp.15.29\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Familial hypercholesterolemia (FH) is the most common single gene disorder of lipid metabolism. Identifying the genetic cause of FH affects the management of the patient and their family members. Traditional genetic testing methods have been limited by throughput and cost, and therefore the majority of patients have not received a molecular diagnosis. Genetic testing technology has made huge advances in recent years, and these advances are now being translated to improve clinical diagnostic testing for many genetic disorders including FH. This review describes these advances in genetic testing, and considers their implications for the diagnosis and treatment of FH.\",\"PeriodicalId\":55252,\"journal\":{\"name\":\"Clinical Lipidology\",\"volume\":\"13 1\",\"pages\":\"379 - 385\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lipidology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/clp.15.29\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lipidology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/clp.15.29","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}
The past, present and future of molecular genetic diagnosis in familial hypercholesterolemia
Abstract Familial hypercholesterolemia (FH) is the most common single gene disorder of lipid metabolism. Identifying the genetic cause of FH affects the management of the patient and their family members. Traditional genetic testing methods have been limited by throughput and cost, and therefore the majority of patients have not received a molecular diagnosis. Genetic testing technology has made huge advances in recent years, and these advances are now being translated to improve clinical diagnostic testing for many genetic disorders including FH. This review describes these advances in genetic testing, and considers their implications for the diagnosis and treatment of FH.
期刊介绍:
The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.